| SCHEDULE OF OTHER INVESTMENTS |
SCHEDULE OF OTHER INVESTMENTS
| | |
As of
June 30, 2026 | | |
As of
December 31, 2025 | |
| | |
(Unaudited) | | |
(Audited) | |
| Investments in equity securities without readily determinable fair values of affiliates: | |
| | | |
| | |
| | |
| | | |
| | |
| Forekast Limited (a) | |
$ | 17,000,000 | | |
$ | - | |
| Greenophene Technologies Limited (b) | |
| 1,200,000 | | |
| - | |
| | |
$ | 18,200,000 | | |
$ | - | |
|
| SCHEDULE OF SHARE EXCHANGE IN CONNECTION WITH MINORITY INVESTMENT |
Set
forth below are the details of the share exchange in connection with the minority investment in Forekast described above, as extracted
from Annex A to the Share Exchange Agreement:
SCHEDULE OF SHARE EXCHANGE IN CONNECTION WITH MINORITY INVESTMENT
| Forekast Shareholders | |
Forekast shares
received
by the Company | | |
The Company’s
Common Stock
received
by Forekast
Shareholders | |
| BHL Ltd. | |
| 520 | | |
| 3,250,000 | |
| Moira Venture Limited | |
| 120 | | |
| 750,000 | |
| Renhari Limited | |
| 180 | | |
| 1,125,000 | |
| Joharne Limited | |
| 180 | | |
| 1,125,000 | |
| Crescent East Limited | |
| 180 | | |
| 1,125,000 | |
| Stratifi Global Limited | |
| 180 | | |
| 1,125,000 | |
| Total shares | |
| 1,360 | | |
| 8,500,000 | |
|
| SCHEDULE OF CARRYING VALUES OF EQUITY SECURITIES WITHOUT READILY DETERMINABLE FAIR VALUES |
During
the six months ended June 30, 2026, and the year ended December 31, 2025, the changes in carrying values of the Investments are as follows:
SCHEDULE OF CARRYING VALUES OF EQUITY SECURITIES WITHOUT READILY DETERMINABLE FAIR VALUES
| | |
As of
June 30, 2026 | | |
As of
December 31, 2025 | |
| | |
(Unaudited) | | |
(Audited) | |
| Original cost | |
| | | |
| | |
| Balance, beginning of period / year | |
$ | 8,330,989 | | |
$ | 8,331,139 | |
| Additions during the period | |
| 18,200,000 | | |
| - | |
| Disposal of impaired investment during the year | |
| - | | |
| (150 | ) |
| Balance, end of period / year | |
| 26,530,989 | | |
| 8,330,989 | |
| | |
| | | |
| | |
| Accumulated impairment | |
| | | |
| | |
| Balance, beginning of period / year | |
| (8,330,989 | ) | |
| (8,319,066 | ) |
| Impairment during the year | |
| - | | |
| (12,073 | ) |
| Disposal of impaired investment during the year | |
| - | | |
| 150 | |
| Balance, end of period / year | |
| (8,330,989 | ) | |
| (8,330,989 | ) |
| | |
| | | |
| | |
| Net carrying values of equity securities without readily determinable fair values | |
$ | 18,200,000 | | |
$ | - | |
|